Sustained complete response to dostarlimab in a metastatic SMARCA4-deficient undifferentiated uterine sarcoma with dMMR/MSI-H and high tumor mutational burden: a case report

SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) is a rare, aggressive malignancy with limited treatment options, and its immunobiology and predictive biomarkers remain poorly characterized. We report a 49-year-old woman with metastatic SDUS who progressed after first-line gemcitabine plus docetaxel. Tumor profiling revealed loss of MSH2 expression, microsatellite instability-high (MSI-H) status, and a tumor mutational burden (TMB) of 35.82 mutations/Mb. Following palliative radiotherapy to a symptomatic left supraclavicular nodal conglomerate, the patient initiated dostarlimab within the phase I GARNET trial and achieved a complete radiological response after six cycles. Treatment was discontinued after 12 cycles because of immune-related duodenitis and arthritis requiring immunosuppressive therapy. At the last follow-up in June 2026, no evidence of disease was detected, approximately 32 months after treatment discontinuation and total duration of complete response of 42 months. To our knowledge, this is the first reported case of SDUS harboring coexisting deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) and TMB-high features in which a durable complete radiological response was observed following dostarlimab treatment. This case highlights the potential value of comprehensive molecular profiling to identify patients who may benefit from immune checkpoint inhibition, although the predictive value of these biomarkers and the efficacy of immunotherapy in SDUS remain to be established.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-18
DOI
https://doi.org/10.3389/fonc.2026.1957417
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Sustained complete response to dostarlimab in a metastatic SMARCA4-deficient undifferentiated uterine sarcoma with dMMR/MSI-H and high tumor mutational burden: a case report

Carmen García-Durán, David García-Illescas, Lourdes Salazar-Huayna, Lorena Fariñas-Madrid et al.
3 links
Frontiers in Oncology
Cancer Immunotherapy and Biomarkers
article

Sustained complete response to dostarlimab in a metastatic SMARCA4-deficient undifferentiated uterine sarcoma with dMMR/MSI-H and high tumor mutational burden: a case report

Carmen García-Durán, David García-Illescas, Lourdes Salazar-Huayna, Lorena Fariñas-Madrid, A.A.A. Geng Cahuayme, Ana Oaknin, Jesús Yaringaño, Ernesto Trallero‐Araguás, Roberta Mazzeo
article en

Abstract

SMARCA4-deficient undifferentiated uterine sarcoma (SDUS) is a rare, aggressive malignancy with limited treatment options, and its immunobiology and predictive biomarkers remain poorly characterized. We report a 49-year-old woman with metastatic SDUS who progressed after first-line gemcitabine plus docetaxel. Tumor profiling revealed loss of MSH2 expression, microsatellite instability-high (MSI-H) status, and a tumor mutational burden (TMB) of 35.82 mutations/Mb. Following palliative radiotherapy to a symptomatic left supraclavicular nodal conglomerate, the patient initiated dostarlimab within the phase I GARNET trial and achieved a complete radiological response after six cycles. Treatment was discontinued after 12 cycles because of immune-related duodenitis and arthritis requiring immunosuppressive therapy. At the last follow-up in June 2026, no evidence of disease was detected, approximately 32 months after treatment discontinuation and total duration of complete response of 42 months. To our knowledge, this is the first reported case of SDUS harboring coexisting deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) and TMB-high features in which a durable complete radiological response was observed following dostarlimab treatment. This case highlights the potential value of comprehensive molecular profiling to identify patients who may benefit from immune checkpoint inhibition, although the predictive value of these biomarkers and the efficacy of immunotherapy in SDUS remain to be established.

Frontiers in OncologyVol. 16
Hebron University (PS), Vall d'Hebron Institut de Recerca (ES), Vall d'Hebron Hospital Universitari (ES), Vall d'Hebron Institute of Oncology (ES)
Good health and well-being
Cancer Immunotherapy and Biomarkers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon